Intravesical valrubicin in the treatment of carcinoma in situ of the bladder

By Steinberg GD   Kuznetsov DD   O’Connor RC   Alsikafi NF  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 6, 2001-06 ,pp. : 1009-1013

Informa Healthcare

Access to resources Recommend Favorite

Phase II Study of CI-958 in Patients with Hormone Refractory Prostate Carcinoma

By Philip Kuebler J.   Moore Timothy   Pritchard James   Kraut Eric  

Investigational New Drugs, Vol. 22, Iss. 2, 2004-04 ,pp. : 181-184

Springer Publishing Company

Access to resources Recommend Favorite

Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma

By Hutson Thomas   Ganapathi Ram   Elson Paul   Mekhail Tarek   Olencki Thomas   Budd G.   Bukowski Ronald  

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 277-284

Springer Publishing Company

Access to resources Recommend Favorite

Two -Year Efficacy and Safety of Botulinum a Toxin Intravesical Injections in Patients Affected by Refractory Painful Bladder Syndrome

By  

Current Drug Delivery, Vol. 7, Iss. 1, 2010-01 ,pp. : 1-4

Bentham Science Publishers

Access to resources Recommend Favorite

Carcinoma in situ of the Urinary Bladder: Review of Clinicopathologic Characteristics with an Emphasis on Aspects Related to Molecular Diagnostic Techniques and Prognosis

By Nese Nalan   Gupta Ruta   Bui Matthew H. T.   Amin Mahul B.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 7, Iss. 1, 2009-01 ,pp. : 48-57

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite